Members
First name: Alexandre Last name: Storto Function: Medical engineer Position: Assistant medical engineer Email: alexandre.storto aphp.fr |
Research interest
My main research interest are HIV physiopathology and resistance. My time is distributed between development of research assays for our research on HIV and evaluation or implementation of commercial assays in the laboratory of medical virology at the university hospital Bichat Claude Bernard. My main areas of expertise are HIV sequencing, with Sanger and new NGS technologies, viral quantification, viral culture and phenotypic testing. I am also working on the bioinformatic field. I am a member of the ANRS AC11 bioinformatic group and participate to the development of bioinformatics pipelines for NGS sequences analysis.
Education
Degree
2007: Assistant engineer training, Ecole Supérieure des Techniques de Biologie Appliquée, Paris
2005: Technical diploma graduate, Lycée Jules Ferry, Cannes
2005: Technical diploma graduate, Lycée Jules Ferry, Cannes
Academic positions
2016-present: Research and medical biology engineer functioning, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
2011- 2016: Medical biology technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
2007-2011: Research technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
2011- 2016: Medical biology technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
2007-2011: Research technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
Research training (post doctoral)
2007-present: Engineering training, Conservatoire National des Arts et Métiers, Paris
2016: 5th school of bioinformatics AVIESAN-IFB “Initiation to the processing of genomic data obtained by high-throughput sequencing”, Roscoff
2016: 5th school of bioinformatics AVIESAN-IFB “Initiation to the processing of genomic data obtained by high-throughput sequencing”, Roscoff
List of the main publications
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1086–1089.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1237-1242.
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1086–1089.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1237-1242.
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
Exhaustive list of publications
2023
Mazouz F, Bertine M, Coppée R, Storto A, Katlama C, Landman R, Cabié A, Peytavin G, Raffi F, Yazdanpanah Y, Descamps D, Joly V, Ghosn J, Charpentier C, LAMIDOL Study Group
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
The Journal of Antimicrobial Chemotherapy 2023, dkad344.
2022
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, Storto A, Lê MP, Abdi B, Ousley J, Kalua T, Calvez V, Jahn A, Marcelin AG, Szumilin E
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
The lancet. HIV 2022, 9, e544-e553.
2021
Lebourgeois S, Storto A, Gout B, Le Hingrat Q, Ardila Tjader G, Cerdan MDC, English A, Pareja J, Love J, Houhou-Fidouh N, Manissero D, Descamps D, Visseaux B
Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2021, 107, 179-181.
Martin A, Storto A, Le Hingrat Q, Collin G, André B, Mallory A, Dangla R, Descamps D, Visseaux B, Gossner O
High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2021, 141, 104895.
Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021
Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2983-2987.
2020
Visseaux B, Le Hingrat Q, Collin G, Ferré V, Storto A, Ichou H, Bouzid D, Poey N, de Montmollin E, Descamps D, Houhou-Fidouh N
Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection.
Journal of Clinical Virology 2020, 129, 104520.
Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, Armenia D, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1026-1030.
2019
Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 614-617.
2018
Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.
Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1039-1044.
Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, ANRS HIV-2 CO5 Cohort
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018
Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
PloS One 2018, 13, e0198334.
2017
Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
HIV medicine 2017, 18, 696-700.
2016
Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.
2015
Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.
Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.
2014
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1086–1089.
2013
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1237-1242.
Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2197-2198.
Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D, ANRS AC11 Resistance Study Group
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2626-2631.
Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.
PloS One 2013
2012
Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.
Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.
Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial Agents and Chemotherapy 2012, 56, 137-139.
2011
Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.
Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.
Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D
High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
Antiviral Therapy 2011, 16, 429-433.
2010
Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D, ANRS AC11 Resistance Study Group
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
The Journal of Antimicrobial Chemotherapy 2010, 65, 2620-2627.